Core Laboratories (CLB) AI Stock Analysis

• Market Cap: $686.34M
• Dividend Yield: 0.27%
• Average Volume (3M): 635.01K
• Price to Earnings (P/E): 21.3
• Beta (1Y): 1.27
• Revenue Growth: -1.02%
• EPS Growth: 6.34%
• Country: US
• Employees: 3,400
• Sector: Energy
• Sector Strength: 52
• Industry: Oil & Gas Equipment & Services
• EPS (TTM): 0.22
• Shares Outstanding: 46,563,390
• 10 Day Avg. Volume: 492,461
• 30 Day Avg. Volume: 635,009
• PEG Ratio: -1.70
• Price to Book (P/B): 3.22
• Price to Sales (P/S): 1.55
• P/FCF Ratio: 18.72
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 1.41
• Enterprise Value/Gross Profit: 8.23
• Enterprise Value/Ebitda: 9.98
• 1Y Price Target: $12.00
• Price Target Upside: -20.21% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.72
• Revenue Forecast (FY): $517.87M

• Rating: 72 Outperform
• Price Target: $16.50 ▲(9.71% Upside)

Core Laboratories demonstrates solid financial performance with consistent revenue growth and effective debt management. Technical indicators show a positive trend, supporting a bullish outlook. However, the stock's high P/E ratio suggests potential overvaluation, and geopolitical challenges present risks. The company's strategic initiatives and earnings call insights provide a cautiously optimistic view, balancing growth potential with existing challenges.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong demand for Core Laboratories' services, particularly in international regions, which supports long-term business sustainability and market expansion.

Improved Operating Margins

Improved operating margins reflect effective cost management and operational efficiency, enhancing profitability and providing a buffer against potential cost pressures.

Strategic Acquisition

The acquisition of Solintec expands Core Laboratories' footprint in Brazil, potentially opening new markets and enhancing service offerings, which can drive long-term growth.

Negative Factors

Decline in Product Sales

Declining product sales indicate challenges in the U.S. onshore market, which could impact revenue streams and necessitate strategic adjustments to maintain growth.

Geopolitical and Tariff Challenges

Geopolitical tensions and tariffs create uncertainty in commodity prices, affecting demand for Core Laboratories' services and potentially hindering growth in volatile markets.

Flat Year-over-Year Revenue

Flat year-over-year revenue growth suggests challenges in maintaining momentum, which could impact long-term financial performance if not addressed through strategic initiatives.

Core Laboratories Business Overview & Revenue Model

Company Description

Core Laboratories (CLB) is a leading provider of proprietary and patented reservoir description, production enhancement, and reservoir management services to the oil and gas industry. Headquartered in Amsterdam, the company operates globally, offering specialized services that include reservoir fluid analysis, enhanced oil recovery, and advanced technologies for well completion and production optimization. Core Laboratories serves a diverse range of clients, from major integrated oil companies to smaller independent operators, and is known for its commitment to innovation and high-quality service delivery.

How the Company Makes Money

Core Laboratories generates revenue through a combination of service contracts, consulting agreements, and the sale of specialized equipment and technologies. The company's primary revenue streams include reservoir description services, which encompass the analysis of reservoir rocks and fluids to help clients optimize hydrocarbon recovery, and production enhancement services that focus on improving the efficiency of existing wells. Additionally, Core Laboratories earns income from its proprietary technologies and products, including advanced tools for reservoir management. Significant partnerships with major oil and gas companies further bolster its revenue, as these collaborations often lead to long-term contracts and recurring business. Market demand for energy and the ongoing need for enhanced production techniques also play crucial roles in driving Core Laboratories' earnings.

Core Laboratories Financial Statement Overview

Summary

Core Laboratories exhibits solid financial health with consistent revenue growth and improving leverage. Profitability margins are stable, though there are slight pressures on EBIT and EBITDA margins. The company has effectively managed its debt levels, enhancing its financial stability. Cash flow metrics indicate strong cash conversion, though operating cash flow coverage could be improved.

Income Statement

Core Laboratories has shown consistent revenue growth, with a TTM growth rate of 2.4%. The company maintains healthy margins, with a gross profit margin of 17.12% and a net profit margin of 6.21% in the TTM. However, there is a slight decline in EBIT and EBITDA margins compared to previous years, indicating potential cost pressures.

Balance Sheet

The company's debt-to-equity ratio has improved significantly to 0.15 in the TTM, indicating better leverage management. Return on equity is strong at 12.24%, reflecting efficient use of equity. However, the equity ratio remains moderate, suggesting room for improvement in asset financing.

Cash Flow

Core Laboratories has demonstrated positive free cash flow growth of 3.92% in the TTM. The operating cash flow to net income ratio is 0.52, showing moderate cash generation relative to net income. The free cash flow to net income ratio is high at 0.91, indicating strong cash conversion, though there is room for improvement in operating cash flow coverage.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	517.50M	523.85M	509.79M	489.74M	470.25M	487.27M
Gross Profit	88.59M	88.37M	94.05M	78.92M	83.84M	102.13M
EBITDA	73.10M	73.27M	70.42M	58.69M	63.78M	70.49M
Net Income	32.12M	31.40M	36.67M	19.45M	19.73M	-97.64M
Balance Sheet
Total Assets	591.36M	590.41M	586.39M	578.35M	580.85M	568.58M
Cash, Cash Equivalents and Short-Term Investments	25.63M	19.16M	15.12M	15.43M	17.70M	13.81M
Total Debt	167.10M	180.14M	215.38M	222.39M	250.26M	326.98M
Total Liabilities	313.97M	332.67M	356.59M	389.40M	419.85M	493.01M
Stockholders Equity	271.35M	251.99M	224.81M	184.26M	156.45M	71.51M
Cash Flow
Free Cash Flow	34.87M	43.36M	14.21M	14.74M	23.04M	45.99M
Operating Cash Flow	50.49M	56.39M	24.79M	24.96M	36.58M	57.87M
Investing Cash Flow	-2.07M	-6.39M	-6.65M	-3.86M	-10.22M	7.85M
Financing Cash Flow	-43.80M	-45.96M	-18.45M	-23.38M	-22.46M	-63.01M

Core Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Positive. The current price of 15.04 is below the 20-day moving average (MA) of 15.38, above the 50-day MA of 13.72, and above the 200-day MA of 12.85, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 52.98 is Neutral, neither overbought nor oversold. The STOCH value of 48.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLB.

Core Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TTI	77 Outperform	$936.23M	7.62	53.71%	―	0.17%	7307.20%
CLB	72 Outperform	$686.34M	21.34	12.31%	0.27%	-1.02%	6.34%
OIS	71 Outperform	$367.44M	16.40	3.31%	―	-11.02%	―
Sector *	65 Neutral	$15.17B	7.61	4.09%	5.20%	3.87%	-62.32%
FTK	64 Neutral	$420.81M	15.68	29.09%	―	23.56%	242.78%
PUMP	60 Neutral	$978.47M	―	-2.05%	―	-11.65%	87.57%
ACDC	42 Neutral	$926.06M	-2.94	-31.46%	―	-11.92%	-53.72%

Core Laboratories Corporate Events

Core Laboratories Reports Steady Q3 2025 Performance

Core Laboratories N.V. is a leading provider of proprietary and patented reservoir description and production enhancement services and products, primarily serving the oil and gas industry worldwide.

Core Laboratories N.V. Earnings Call: Growth Amid Challenges

Core Laboratories N.V. Earnings Call Reveals Mixed Performance Amid Growth and Challenges

Core Laboratories Announces Q3 2025 Financial Results

On October 22, 2025, Core Laboratories Inc. announced its third quarter 2025 financial results, highlighting a revenue of $134.5 million, which was up over 3% sequentially but flat year-over-year. The company reported an operating income of $20.9 million and a GAAP EPS of $0.30. Core Lab also completed the acquisition of Solintec, a Brazilian geological services provider, to enhance its capabilities in the South Atlantic Margin. The company repurchased 462,248 shares and declared a quarterly cash dividend, demonstrating its commitment to returning value to shareholders. Additionally, Core Lab’s leverage ratio improved to its lowest level in nine years, indicating strong financial health and strategic positioning for future growth.

The most recent analyst rating on (CLB) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Core Laboratories stock, see the CLB Stock Forecast page.